BMD Screening Frequency Recommendations
The evidence on optimal BMD rescreening intervals is limited, but based on baseline T-scores, repeat DXA screening should occur at approximately 15 years for normal BMD or mild osteopenia, 5 years for moderate osteopenia, and 1 year for advanced osteopenia in women aged 65 and older. 1
Current Guideline Position
The 2025 USPSTF guideline explicitly acknowledges that evidence related to screening intervals for osteoporosis is limited and calls for more research to inform appropriate screening intervals 1. Despite this limitation, the guideline recommends initial screening for:
- All women aged 65 years and older
- Postmenopausal women younger than 65 years with elevated fracture risk (using a 2-step approach with risk assessment tools followed by DXA if indicated)
Evidence-Based Rescreening Intervals
The most robust data comes from a landmark 2012 study in the New England Journal of Medicine that followed 4,957 women aged 67+ for up to 15 years 2. This study provides the clearest framework for rescreening intervals:
Stratified by Baseline T-Score:
- Normal BMD (T-score ≥ -1.0): 16.8 years (95% CI: 11.5-24.6 years)
- Mild osteopenia (T-score -1.01 to approximately -1.5): 17.3 years (95% CI: 13.9-21.5 years)
- Moderate osteopenia (T-score approximately -1.5 to -2.0): 4.7 years (95% CI: 4.2-5.2 years)
- Advanced osteopenia (T-score -2.0 to -2.49): 1.1 years (95% CI: 1.0-1.3 years)
These intervals represent the estimated time for 10% of women to transition to osteoporosis before experiencing a hip or clinical vertebral fracture 2.
Supporting Evidence from Asian Populations
A 2022 study in Asian women confirmed similar patterns with adjusted intervals of 13.2 years for mild osteopenia, 5.0 years for moderate osteopenia, and 1.5 years for severe osteopenia 3. This cross-ethnic validation strengthens the reliability of T-score-based rescreening strategies.
Clinical Algorithm for Rescreening
For women ≥65 years after initial screening:
- T-score ≥ -1.5 (normal or mild osteopenia): Rescreen in 10-15 years or not at all if life expectancy is limited
- T-score -1.5 to -2.0 (moderate osteopenia): Rescreen in 5 years
- T-score -2.0 to -2.49 (advanced osteopenia): Rescreen in 1-2 years
- T-score ≤ -2.5 (osteoporosis): Initiate treatment; rescreening intervals depend on treatment response
Important Caveats
Limited Value of Short-Interval Rescreening
A 2013 Framingham study demonstrated that repeating BMD after 4 years did not meaningfully improve fracture risk prediction beyond baseline BMD in untreated adults (mean age 75 years) 4. The area under the ROC curve improved minimally from 0.71 to 0.72 when adding BMD change to baseline BMD 4. This suggests that rescreening within 4 years is unlikely to be beneficial in most untreated patients with normal or mildly low BMD.
Patients on Treatment
The evidence above applies primarily to untreated patients. Those initiated on bisphosphonates or other osteoporosis therapies require different monitoring strategies, though specific intervals are not well-established in the guidelines provided.
Men
Evidence for men is sparse. Some experts recommend initiating BMD screening at age 70 in men 5, but optimal rescreening intervals are not well-defined. The same T-score-based approach used in women is reasonable to apply.
Younger Postmenopausal Women (<65 years)
For women under 65 with risk factors who undergo initial screening, apply the same T-score-based rescreening intervals as older women 2.
Common Pitfalls to Avoid
- Over-screening: Repeating DXA annually in patients with normal or mildly low BMD wastes resources and provides minimal clinical benefit 4, 2
- Ignoring baseline T-score: The baseline T-score is the strongest predictor of rescreening interval; one-size-fits-all approaches are inappropriate 2
- Screening too young without risk factors: The 2025 USPSTF does not provide specific screening intervals for those under 65, emphasizing risk-based initial screening 1